✉news ScienceScience first seen 21 h ago, last 17 h ago, peak #21

Yan Leyfman Presents Real-World Osimertinib Outcomes in EGFR-Mutant Lung Cancer

Original: Yan Leyfman: Real-World Outcomes After First-Line Osimertinib in EGFR-Mutant NSCLC

Oncologist and researcher Yan Leyfman reported real-world data on outcomes after first-line osimertinib treatment in patients with EGFR-mutated non-small cell lung cancer. The presentation highlights how the targeted therapy performs outside clinical trial settings, a topic of interest to oncologists tracking effectiveness and resistance patterns in routine care.

Why now: Oncology specialists are following new real-world evidence on osimertinib, the standard first-line therapy for EGFR-mutated lung cancer.

Yan LeyfmanosimertinibEGFR-mutated NSCLC

Open on news →

Rank over time, top of the chart is #1. 4 snapshots from 21 h ago to 17 h ago.

Evidence

• Yan Leyfman: Real-World Outcomes After First-Line Osimertinib in EGFR-Mutant NSCLC · Oncodaily

API: https://socialmediatrends-api.osmike.com/v1/trends/893932